Extina

Extina is a brand name of ketoconazole topical, approved by the FDA in the following formulation(s):

EXTINA (ketoconazole - aerosol, foam; topical)

• 
  Manufacturer: STIEFEL LABS INC
  
  Approval date: June 12, 2007
  
  Strength(s): 2% ^[RLD][AT]

Has a generic version of Extina been approved?

A generic version of Extina has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Extina and have been approved by the FDA:

ketoconazole aerosol, foam; topical

• 
  Manufacturer: PERRIGO ISRAEL
  
  Approval date: August 25, 2011
  
  Strength(s): 2% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Extina. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Topical antifungal composition
  Patent 7,553,835
  Issued: June 30, 2009
  Inventor(s): Davey; Greg & Abram; Albert Zorko
  Assignee(s): Stiefel Research Australia Pty Ltd
  The subject matter relates to a topical, foamable composition including at least one antifungal agent, said composition characterised in that said at least one antifungal agent is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and in that it has a residual non-volatile component content of less than 25%. The subject matter furthermore relates to a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis by applying to the affected area of a patient requiring such treatment the antifungal composition.
  
  Patent expiration dates:
  
  
  • October 19, 2018
    
    ✓ 
    Patent use: TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
    ✓ 
    Drug product
  
  



• 
  Topical antifungal composition
  Patent 8,026,238
  Issued: September 27, 2011
  Inventor(s): Davey; Greg & Abram; Albert Zorko
  Assignee(s): Stiefel Research Australia, Pty Ltd
  A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content of less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of a patient requiring such treatment an antifungal composition.
  
  Patent expiration dates:
  
  
  • October 19, 2018
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETETENT PATIENTS 12 YEARS OF AGE AND OLDER
    ✓ 
    Drug product
  
  

See also...

• Extina Consumer Information (Drugs.com)
• Extina Foam Consumer Information (Wolters Kluwer)
• Extina Consumer Information (Cerner Multum)
• Extina Topical Advanced Consumer Information (Micromedex)
• Ketoconazole Cream Consumer Information (Wolters Kluwer)
• Ketoconazole Foam Consumer Information (Wolters Kluwer)
• Ketoconazole Gel Consumer Information (Wolters Kluwer)
• Ketoconazole Shampoo Consumer Information (Wolters Kluwer)
• Ketoconazole topical Consumer Information (Cerner Multum)
• Ketoderm Topical Advanced Consumer Information (Micromedex)
• Ketoconazole Topical Advanced Consumer Information (Micromedex)
• Ketoconazole topical AHFS DI Monographs (ASHP)